IAG, Image Analysis Group, a strategic imaging partner for bio-pharma companies, announced they have entered into an collaboration with IMV’s to validate how advanced imaging techniques can help assess the tumor microenvironment in a subset of patients in IMV’s ongoing phase 2 basket trial, which is evaluating DPX-Survivac in combination with pembrolizumab in multiple solid tumor indications.
Robust financing to support advancement of Immusoft’s novel B cell platform
Immusoft Receives Rare Pediatric Disease Designation for Treatment of MPS I
Acquisition Adds Fast-Acting Neurotoxin Programs with 2 to 4-Week Duration to Allergan's Best-in-Class Medical Aesthetics Portfolio and Pipeline
Federal grant will be used to help company advance B cell technology